康氏乙肝合剂联合干扰素治疗慢性乙型肝炎41例

Clinical Study of Combined Treatment with Kang's Hepatitis B Mixture and Interferon on Chronic Hepatitis B

目的:研究康氏乙肝合剂联合干扰素治疗慢性乙型肝炎的临床疗效。方法:选择慢性乙型肝炎的病例,应用康氏乙肝合荆联合干扰素进行治疗,以单独应用康氏乙肝合剂和单独应用干扰素治疗的患者进行对比观察,疗程均为6个月。观察患者治疗前后肝功能、乙肝病毒标志物的变化情况。结果:在肝功能复常方面,治疗组优于两对照组,但无统计学差异,P>0.05;在HBeAg、HBV DNA阴转方面,治疗组明显优于对照组,统计学处理差异有显著性意义,P<0.01或0.05。结论:康氏乙肝合剂联合干扰素治疗慢性乙型肝炎具有较好疗效,康氏乙肝合剂能明显提高干扰素的抗乙肝病毒效果。

Objective: To study the clinical curative effect of combined treatment with Kang's hepatitis B mixture and In-terferon in treating chronic hepatitis B. Methods: Therapeutic group treated with Kang's hepatitis B mixture and Interferon contrast group A and B treated only by Kang's hepatitis B mixture or Interferon respectively; all to treat 6 months; the liver function and hepatitis B virus indicates were observed. Results: Aspect at turning negative for the liver function and HBsAg, therapeutic group was superior to contrast group A and B, but did not have statistics difference, P>0.05. Aspect at turning negative for HBeAg, HBV DNA, group was clearly superior to contrast groups, and had significance difference, P<0.01 or 0.05. Conclusion: It is good therapeutic method that combined treatment with Kang's hepatitis B mixture and Interferon.